Ditazole

Identification

Name
Ditazole
Accession Number
DB08994
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Ditazole is a non-steroidal anti-inflammatory agent with analgesic and antipyretic activity similar to phenylbutazone. Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.

Structure
Thumb
Synonyms
  • 2,2'-(4,5-Diphenyloxazol-2-ylazanediyl)diethanol
External IDs
S-222
International/Other Brands
Ageroplas (Farma Lepori)
Categories
UNII
H2BQI5Z8FT
CAS number
18471-20-0
Weight
Average: 324.3737
Monoisotopic: 324.147392516
Chemical Formula
C19H20N2O3
InChI Key
UUCMDZWCRNZCOY-UHFFFAOYSA-N
InChI
InChI=1S/C19H20N2O3/c22-13-11-21(12-14-23)19-20-17(15-7-3-1-4-8-15)18(24-19)16-9-5-2-6-10-16/h1-10,22-23H,11-14H2
IUPAC Name
2-[(diphenyl-1,3-oxazol-2-yl)(2-hydroxyethyl)amino]ethan-1-ol
SMILES
OCCN(CCO)C1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabDitazole may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolDitazole may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ditazole.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Ditazole.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Ditazole.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ditazole.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Ditazole.Approved
AncrodDitazole may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Ditazole.Investigational
Antithrombin III humanDitazole may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanDitazole may increase the anticoagulant activities of Apixaban.Approved
AprotininThe therapeutic efficacy of Ditazole can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinDitazole may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanDitazole may increase the anticoagulant activities of Argatroban.Approved, Investigational
AzelastineAzelastine may increase the anticoagulant activities of Ditazole.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ditazole.Approved, Investigational
BecaplerminDitazole may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Ditazole.Investigational
BivalirudinDitazole may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BuflomedilBuflomedil may increase the anticoagulant activities of Ditazole.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Ditazole.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Ditazole.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Ditazole.Experimental, Investigational
CertoparinDitazole may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolCilostazol may increase the anticoagulant activities of Ditazole.Approved, Investigational
ClopidogrelClopidogrel may increase the anticoagulant activities of Ditazole.Approved
CloricromenCloricromen may increase the anticoagulant activities of Ditazole.Experimental
Dabigatran etexilateDitazole may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinDitazole may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDitazole may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanDitazole may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ditazole.Approved, Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Ditazole.Investigational
DesirudinDitazole may increase the anticoagulant activities of Desirudin.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Ditazole.Approved, Investigational
DextranDitazole may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacThe risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Ditazole.Approved, Vet Approved
DicoumarolDitazole may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ditazole.Approved, Investigational
DipyridamoleDipyridamole may increase the anticoagulant activities of Ditazole.Approved
Edetic AcidDitazole may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDitazole may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinDitazole may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Ditazole.Approved, Investigational
EplivanserinEplivanserin may increase the anticoagulant activities of Ditazole.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Ditazole.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ditazole.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Ditazole.Approved, Investigational, Vet Approved
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Ditazole.Approved
Ethyl biscoumacetateDitazole may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidDitazole may increase the anticoagulant activities of Ferulic acid.Experimental
FluindioneDitazole may increase the anticoagulant activities of Fluindione.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Ditazole.Approved, Vet Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Ditazole.Approved, Investigational
FondaparinuxDitazole may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateDitazole may increase the anticoagulant activities of Gabexate.Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Ditazole.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Ditazole.Experimental
HeparinDitazole may increase the anticoagulant activities of Heparin.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Ditazole.Investigational
IbudilastIbudilast may increase the anticoagulant activities of Ditazole.Approved, Investigational
IbuprofenThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ditazole.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ditazole.Approved, Investigational, Nutraceutical
IdraparinuxDitazole may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ditazole.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Ditazole.Investigational
IloprostIloprost may increase the anticoagulant activities of Ditazole.Approved, Investigational
IndobufenIndobufen may increase the anticoagulant activities of Ditazole.Investigational
KetanserinKetanserin may increase the anticoagulant activities of Ditazole.Investigational
KetorolacThe risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Ditazole.Approved
LepirudinDitazole may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanDitazole may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelLevonorgestrel may decrease the anticoagulant activities of Ditazole.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ditazole.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Ditazole.Experimental
MelagatranDitazole may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ditazole.Approved
Methyl salicylateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Ditazole.Approved, Vet Approved
MilrinoneMilrinone may increase the anticoagulant activities of Ditazole.Approved
NadroparinDitazole may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatDitazole may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of bleeding can be increased when Naftopidil is combined with Ditazole.Investigational
NaproxenThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Ditazole.Approved, Vet Approved
NimesulideThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ditazole.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ditazole.Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ditazole.Approved
OtamixabanDitazole may increase the anticoagulant activities of Otamixaban.Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Ditazole.Approved, Investigational
Pentaerythritol TetranitrateDitazole may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateDitazole may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Ditazole.Approved, Investigational
PhenindioneDitazole may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonDitazole may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Ditazole.Approved
PicotamidePicotamide may increase the anticoagulant activities of Ditazole.Experimental
Potassium CitrateDitazole may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Ditazole.Approved
Protein CDitazole may increase the anticoagulant activities of Protein C.Approved
Protein S humanDitazole may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDitazole may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ditazole.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Ditazole.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Ditazole.Approved, Experimental, Investigational
ReviparinDitazole may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Ditazole.Approved
RivaroxabanDitazole may increase the anticoagulant activities of Rivaroxaban.Approved
Salicylic acidThe risk or severity of bleeding can be increased when Salicylic acid is combined with Ditazole.Approved, Investigational, Vet Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Ditazole.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Ditazole.Approved, Vet Approved
Sodium CitrateSodium Citrate may increase the anticoagulant activities of Ditazole.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Ditazole.Investigational
SulfasalazineThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Ditazole.Approved
SulindacThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Ditazole.Approved, Investigational
SulodexideDitazole may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TesmilifeneTesmilifene may increase the anticoagulant activities of Ditazole.Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Ditazole.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Ditazole.Approved
TirofibanTirofiban may increase the anticoagulant activities of Ditazole.Approved
Tolfenamic AcidThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Ditazole.Approved, Investigational
TranilastThe risk or severity of bleeding can be increased when Tranilast is combined with Ditazole.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ditazole.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Ditazole is combined with Treprostinil.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Ditazole.Approved, Investigational
Trolamine salicylateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ditazole.Approved
TroxerutinDitazole may increase the anticoagulant activities of Troxerutin.Investigational
VenlafaxineVenlafaxine may increase the antiplatelet activities of Ditazole.Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Ditazole.Approved
WarfarinDitazole may increase the anticoagulant activities of Warfarin.Approved
XimelagatranDitazole may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D07138
PubChem Compound
29088
PubChem Substance
310264955
ChemSpider
27061
ChEBI
135383
ChEMBL
CHEMBL2104306
Drugs.com
Drugs.com Drug Page
Wikipedia
Ditazole
ATC Codes
B01AC01 — Ditazole

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.146 mg/mLALOGPS
logP2.86ALOGPS
logP2.93ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)15.27ChemAxon
pKa (Strongest Basic)-0.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area69.73 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity93.03 m3·mol-1ChemAxon
Polarizability35.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Oxazoles
Direct Parent
Phenyl-1,3-oxazoles
Alternative Parents
Dialkylarylamines / 2,4,5-trisubstituted oxazoles / Benzene and substituted derivatives / Heteroaromatic compounds / Oxacyclic compounds / Azacyclic compounds / Alkanolamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenyl-1,3-oxazole / 2,4,5-trisubstituted 1,3-oxazole / Dialkylarylamine / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound / Oxacycle / Azacycle / Alkanolamine / Organic oxygen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 16, 2014 12:29 / Updated on August 02, 2018 06:12